Status:
NO_LONGER_AVAILABLE
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Lead Sponsor:
Hope Biosciences Research Foundation
Conditions:
Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility:
All Genders
Brief Summary
This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropath...
Detailed Description
An informed consent form will be given to the participant, who will sign before any procedures. The informed consent form will include information about this expanded access and all the aspects consi...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patient diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, with documented medical records.
- Patient must have banked his stem cells at Hope Biosciences LLC.
- Exclusion Criteria
- The patient has any active infection requiring medications.
- The patient has any suicidal ideation during the screening visit or at any point during the study.
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04825626
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, United States, 77478